Detail page

Knowledge Web

Person

Marino Venerito (1975-)

Arzt

Name	Marino Venerito
Time	1975- (Date of birth and death)
Place	Francavilla Fontana, Apulien, Italien (Geburtsort) Sonstiges Ausland / Unbekanntes Land
Gender	männlich
Academic degree	Prof. Dr. med.
Profession	Arzt (characteristic profession)
Further information	FA für Innere Medizin und Gastroenterologie; Universitätskllinikum Magdeburg, Universitätsklinik für Gastroenterologie, Hepatologie und Infektiologie, Leiter des Bereichs Gastrointestinale Onkologie
Record type	Person
GND-Identifier	143142216
Record ID	143142216
Involved in show all Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma : A European Retrospective Multicenter Study Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study First genome-wide association study reveals immune-mediated aetiopathology in idiopathic achalasia ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer—The Randomized Multicenter Phase II NEPAFOX Trial Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports Blauer Teil: Krankheitsbilder in der Gastroenterologie und Hepatologie: Krankheitsbilder - Ösophagus, Magen und Duodenum Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: a multicenter real world cohort Einfluss der prätherapeutischen CT-Diagnostik auf die Therapieentscheidungen bei kolorektalen Karzinomen im Darmzentrum am St. Franziskus-Hospital Münster : eine Retrospektive Analyse Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab Systemic treatment of recurrent hepatocellular carcinoma after liver transplantation: A multicenter trial Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer Comparison of the management of Helicobacter pylori infection between the older and younger European populations Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC) Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC) Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study Gastroduodenale Ulkuskrankheit und Helicobacter pylori Autoimmungastritis Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: Experience from four tertiary centers Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison Proteomics signature of autoimmune atrophic gastritis: towards a link with gastric cancer Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with hepatocellular carcinoma and alpha-fetoprotein ≥ 400 ng/ml : a matching-adjusted indirect comparison Inflammatory microRNAs in gastric mucosa are modulated by Helicobacter pylori infection and proton-pump inhibitors but not by aspirin or NSAIDs Advanced pancreatic ductal adenocarcinoma : moving forward Expression von Cyclooxygenasen (COX-1 und COX-2) und Lipoxygenase (5-LOX) in Nasenpolypen und Bronchialschleimhaut bei Patienten mit Asthma bronchiale, rezidivierender Polyposis nasi und Analgetikainteroleranz : Korrelation mit klinischen und funktionellen Parametern Review : prevention and management of gastric cancer Sicherheit und Effektivität der CT-gestützten HDR-Brachytherapie von abdominalen Lymphknotenmetastasen S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature Maintenance therapy with FOLFIRI after FOLFIRINOX for advanced pancreatic ductal adenocarcinoma : a retrospective single-center analysis Helicobacter pylori Infection: New Facts in Clinical Management Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection Recurrent diffuse gastric bleeding as a leading symptom of gastrointestinal AL amyloidosis Prevalence of Helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany – a region at intermediate risk for gastric cancer Influence of laboratory-related and endoscopy-related factors on the assessment of serum pepsinogens and gastrin-17 Magenkarzinom: Risikopatienten identifizieren und Schlimmeres verhindern Charakterisierung der atrophischen Gastritis in Abhängigkeit der Ätiologie und ihre Bedeutung als präneoplastische Kondition in der Ösophagus- und Magenkarzinogenese Charakterisierung der atrophischen Gastritis in Abhängigkeit der Ätiologie und ihre Bedeutung als präneoplastische Kondition in der Ösophagus- und Magenkarzinogenese Short-term - low-dose aspirin-induced gastric and duodenal erosions are not dependent on the Helicobacter pylori-infection, cyclooxygenase expression and prostaglandin E_tn2 levels Helicobacter pylori -induced downregulation of the secretory leukocyte protease inhibitor (SLPI) in gastric epithelial cell lines and its functional relevance for H. pylori -mediated diseases

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Marino Venerito (1975-)

Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population

Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events

Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma : A European Retrospective Multicenter Study

Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study

First genome-wide association study reveals immune-mediated aetiopathology in idiopathic achalasia

ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer—The Randomized Multicenter Phase II NEPAFOX Trial

Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial

Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports

Blauer Teil: Krankheitsbilder in der Gastroenterologie und Hepatologie: Krankheitsbilder - Ösophagus, Magen und Duodenum

Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: a multicenter real world cohort

Einfluss der prätherapeutischen CT-Diagnostik auf die Therapieentscheidungen bei kolorektalen Karzinomen im Darmzentrum am St. Franziskus-Hospital Münster : eine Retrospektive Analyse

Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab

Systemic treatment of recurrent hepatocellular carcinoma after liver transplantation: A multicenter trial

Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer

Comparison of the management of Helicobacter pylori infection between the older and younger European populations

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis

Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice

Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study

Gastroduodenale Ulkuskrankheit und Helicobacter pylori

Autoimmungastritis

Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience

Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: Experience from four tertiary centers

Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison

Proteomics signature of autoimmune atrophic gastritis: towards a link with gastric cancer

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort

Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with hepatocellular carcinoma and alpha-fetoprotein ≥ 400 ng/ml : a matching-adjusted indirect comparison

Inflammatory microRNAs in gastric mucosa are modulated by Helicobacter pylori infection and proton-pump inhibitors but not by aspirin or NSAIDs

Advanced pancreatic ductal adenocarcinoma : moving forward

Expression von Cyclooxygenasen (COX-1 und COX-2) und Lipoxygenase (5-LOX) in Nasenpolypen und Bronchialschleimhaut bei Patienten mit Asthma bronchiale, rezidivierender Polyposis nasi und Analgetikainteroleranz : Korrelation mit klinischen und funktionellen Parametern

Review : prevention and management of gastric cancer

Sicherheit und Effektivität der CT-gestützten HDR-Brachytherapie von abdominalen Lymphknotenmetastasen

S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study

NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization

The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature

Maintenance therapy with FOLFIRI after FOLFIRINOX for advanced pancreatic ductal adenocarcinoma : a retrospective single-center analysis

Helicobacter pylori Infection: New Facts in Clinical Management

Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection

Recurrent diffuse gastric bleeding as a leading symptom of gastrointestinal AL amyloidosis

Prevalence of Helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany – a region at intermediate risk for gastric cancer

Influence of laboratory-related and endoscopy-related factors on the assessment of serum pepsinogens and gastrin-17

Magenkarzinom: Risikopatienten identifizieren und Schlimmeres verhindern

Charakterisierung der atrophischen Gastritis in Abhängigkeit der Ätiologie und ihre Bedeutung als präneoplastische Kondition in der Ösophagus- und Magenkarzinogenese

Charakterisierung der atrophischen Gastritis in Abhängigkeit der Ätiologie und ihre Bedeutung als präneoplastische Kondition in der Ösophagus- und Magenkarzinogenese

Short-term - low-dose aspirin-induced gastric and duodenal erosions are not dependent on the Helicobacter pylori-infection, cyclooxygenase expression and prostaglandin E_tn2 levels

Helicobacter pylori -induced downregulation of the secretory leukocyte protease inhibitor (SLPI) in gastric epithelial cell lines and its functional relevance for H. pylori -mediated diseases